Neurocrine Biosciences announced the U.S. Food and Drug Administration has approved INGREZZA capsules for the treatment of adults with chorea associated with Huntington’s disease. INGREZZA is the only selective vesicular monoamine transporter 2 inhibitor that offers an effective starting dosage that can be adjusted by a patient’s healthcare provider based on response and tolerability, with no complex titration. Only INGREZZA offers simple dosing that is always one capsule, once daily.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- Neurocrine price target raised to $132 from $130 at Canaccord
- Neurocrine price target raised to $135 from $127 at Cantor Fitzgerald
- Neurocrine price target raised to $125 from $120 at TD Cowen
- Neurocrine price target raised to $112 from $111 at Mizuho
- Neurocrine price target raised to $148 from $140 at Baird